# Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/ABEO/abeona-therapeutics-announces-participation-in-upcoming-investor-conferences-017a6b95
Ticker: ABEO
Company: Abeona Therapeutics
Source: Abeona Therapeutics
Published: 2026-09-02 11:30 EST
Original Source URL: https://investors.abeonatherapeutics.com/news-events/press-releases/detail/354/abeona-therapeutics-announces-participation-in-upcoming-investor-conferences
## Summary

CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team…...

## Article Body
September 02, 2026 7:30am EDT

CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2026:

Cantor Global Healthcare Conference 2026: Fireside chat on Wednesday, September 9, 2026, at 8:00 a.m. ET and investor meetings.

H.C. Wainwright 28th Annual Global Investment Conference: Company presentation on Tuesday, September 15, 2026, at 12:00 p.m. ET and investor meetings.

Morgan Stanley 24th Annual Global Healthcare Conference: Fireside chat on Wednesday, September 16, 2026, at 11:30 a.m. ET and investor meetings.

Live webcasts of the fireside chats and company presentation can be accessed on the Investors section of the Abeona website under “Events” at https://investors.abeonatherapeutics.com/events , where replays of available events will also be accessible for a limited time.

About Abeona Therapeutics Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN ® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com .

ZEVASKYN ® , Abeona Assist ® , Abeona Therapeutics ® , and their related logos are trademarks of Abeona Therapeutics Inc.

Contacts: Investor and Media: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com Investor: Lee M. Stern Meru Advisors lstern@meruadvisors.com

Source: Abeona Therapeutics Inc. Released September 2, 2026
## Recent Company News
- 2026-09-02 11:30 EST — [Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences](https://biopharmsignal.com/news/ABEO/abeona-therapeutics-announces-participation-in-upcoming-investor-conferences-017a6b95) — Source: Abeona Therapeutics
- 2026-09-01 11:30 EST — [Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listin-000ee332) — Source: Abeona Therapeutics
- 2026-08-13 11:30 EST — [Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update](https://biopharmsignal.com/news/ABEO/abeona-therapeutics-reports-second-quarter-2026-results-and-provides-business-up-5235c160) — Source: Abeona Therapeutics
- 2026-08-06 11:30 EST — [Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026](https://biopharmsignal.com/news/ABEO/abeona-therapeutics-to-host-second-quarter-2026-financial-results-conference-cal-9a5111ba) — Source: Abeona Therapeutics
- 2026-08-04 11:30 EST — [CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cms-grants-new-technology-add-on-payment-ntap-status-for-zevaskyn-300aae33) — Source: Abeona Therapeutics
## Related News
- 2026-09-04 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e23953dd)
- 2026-09-04 20:05 EST — RPID — [Rapid Micro Biosystems to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-upcoming-investor-conferences-91a8800f)
- 2026-09-04 20:05 EST — LIXT — [NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS](https://biopharmsignal.com/news/LIXT/nomad-power-solutions-announces-adjournment-of-special-meeting-of-stockholders-74cd9e2e)
- 2026-09-04 20:05 EST — AVTX — [Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-lis-cc7baaf2)
- 2026-09-04 20:05 EST — NTLA — [Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-250d5dd9)